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Abstract
Background: When treating schizophrenia, improving patients’ productivity level is a major goal considering
schizophrenia is a leading cause of functional disability. Productivity level has been identified as the most preferred
treatment outcome by patients with schizophrenia. However, little has been done to systematically investigate
productivity levels in schizophrenia. We set out to better understand the change in productivity level among
chronically ill patients with schizophrenia treated with olanzapine compared with other antipsychotic medications.
We also assessed the links between productivity level and other clinical outcomes.
Methods: This post hoc analysis used data from 6 randomized, double-blind clinical trials of patients with
schizophrenia or schizoaffective disorder, with each trial being of approximately 6 months duration. Change in
productivity level was compared between olanzapine-treated patients (HGBG, n = 172; HGHJ, n = 277; HGJB, n =
171; HGLB, n = 281; HGGN, n = 159; HGDH, n = 131) and patients treated with other antipsychotic medications
(separately vs. haloperidol [HGGN, n = 97; HGDH, n = 132], risperidone [HGBG, n = 167; HGGN, n = 158], quetiapine
[HGJB, n = 175], ziprasidone [HGHJ, n = 271] and aripiprazole [HGLB, n = 285]). Productivity was defined as
functional activities/work including working for pay, studying, housekeeping and volunteer work. Productivity level
in the prior 3 months was assessed on a 5-point scale ranging from no useful functioning to functional activity/
work 75% to 100% of the time.
Results: Chronically ill patients treated with olanzapine (OLZ) experienced significantly greater improvement in
productivity when compared to patients treated with risperidone (RISP) (OLZ = 0.22 ± 1.19, RISP = -0.03 ± 1.17, p =
0.033) or ziprasidone (ZIP) (OLZ = 0.50 ± 1.38, ZIP = 0.25 ± 1.27, p = 0.026), but did not significantly differ from the
quetiapine, aripiprazole or haloperidol treatment groups. Among first episode patients, OLZ therapy was associated
with greater improvements in productivity levels compared to haloperidol (HAL), during the acute phase (OLZ =
-0.31 ± 1.59, HAL = -0.69 ± 1.56, p = 0.011) and over the long-term (OLZ = 0.10 ± 1.50, HAL = -0.32 ± 1.91, p =
0.008). Significantly more chronically ill and first episode patients treated with olanzapine showed moderately high
(>50%-75% of the time) and high levels of productivity (>75%-100% of the time) at endpoint, when compared to
risperidone or haloperidol-treated patients (p < .05), respectively. Higher productivity level was associated with
significantly higher study completion rates and better scores on the positive, negative, disorganized thoughts,
hostility and depression subscales of the Positive and Negative Symptom Scale (PANSS).
Conclusions: Some antipsychotic medications significantly differed in beneficial impact on productivity level in the
long-term treatment of patients with schizophrenia. Findings further highlight the link between clinical and
functional outcomes, showing significant associations between higher productivity, lower symptom severity and
better persistence on therapy.
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Schizophrenia is a severe and lifelong mental illness
characterized by impairment of most domains of cogni-
tive functioning, often leading to functional disability
[1]. Patients with schizophrenia suffer not only from
symptoms such as delusions or hallucinations but also
impaired occupational functioning and low levels of pro-
ductivity (e.g., paid employment, being a student, or
other useful activity) and high rates of unemployment
[2-4].
The poor productivity level among patients with schi-
zophrenia has long been recognized as a core compo-
nent of the burden of illness and its economic cost
[5,6]. The financial cost of schizophrenia in the United
States in 2002 was estimated to be $62.7 billion [6]. In
another study of the economic burden of schizophrenia
in the United States in 2002, the indirect excess cost
due to unemployment was found to be the largest com-
ponent of the overall excess annual costs [7].
Improving patients’ productivity level is an important
goal in the treatment of schizophrenia and was pre-
viously identified as the most preferred treatment out-
come, more than improvement of symptoms, by
clinicians, patients, their families as well as public policy
makers [8]. Rosenheck et al. (2005) [9] evaluated the
personal outcome preferences of a large sample of
patients treated for schizophrenia and identified work as
the 4th preferred outcome among 6 assessed domains
including social life, energy, symptoms, work, confusion
and treatment-emergent adverse events. Importantly,
several clinical guidelines [10-12] cite supported employ-
ment programs as one of the most valuable psychosocial
treatment interventions for schizophrenia.
Although little is known about predictors of produc-
tivity level in the treatment of patients with schizophre-
nia, the link between medication adherence or
persistence and functional outcomes has been consis-
tently shown [13-15]. Adherence to antipsychotic treat-
ment is associated with better long-term improvements
in outcome measures including decreased risk of psy-
chiatric hospitalizations, detentions, victimizations, sub-
stance use, and severity of alcohol-related issues, as well
as improvements in mental health and satisfaction with
social life in general [14]. In addition, longer treatment
duration with antipsychotics (persistence) was found to
be associated with improved symptom severity levels
[16] and greater functional outcomes in the treatment
of patients with schizophrenia [15]. Recent meta-ana-
lyses have shown that antipsychotics significantly differ
on their pharmacology, efficacy, safety and tolerability
profiles [17,18]. The choice of antipsychotics may also
play a significant role in patients’ adherence to or persis-
tence with antipsychotic medications, as adherence and
persistence on antipsychotic medication appear to be
highly intercorrelated [19]. Olanzapine treatment is
associated with better persistence, or lower rates of
medication discontinuation for any cause, compared to
other antipsychotics [20-24]. Moreover, few studies have
suggested that this advantage may be due to the greater
efficacy of olanzapine relative to other antipsychotics
[21,22]. However, it is unclear whether these differences
have any impact on the patient’s productivity level.
Taken together, productivity is a very important area
in the treatment of schizophrenia and yet it is largely
unstudied. To our knowledge, there has not been any
systematic investigation on the comparative productivity
among antipsychotic drugs. To address this question, we
conducted a post hoc analysis of double-blind, active-
controlled trials from Lilly clinical trial database com-
paring olanzapine with other antipsychotic drugs on
change in level of productivity. The links between pro-
ductivity and symptom severity and between productiv-
ity and patients’ persistence on therapy were also
investigated.
Methods
Data source
A post hoc analysis of six randomized, double-blind
clinical trials of patients with schizophrenia or schizoaf-
fective disorders was performed. Participants from 5
randomized clinical trials were chronically ill, whereas
participants in one study were patients experiencing
their first schizophrenic episode (i.e., “first episode
patients”). Trials that studied chronically ill patients ran-
ged between 22 and 28 weeks in duration. The study of
first episode patients included an acute phase (first 12
weeks) and the longer-term phase (the following 24
weeks). These 6 studies have been previously published
comparing olanzapine with risperidone (HGBG, OLZ:
10 to 20 mg/day; RISP: 4 to 12 mg/day) [25], quetiapine
(HGJB, OLZ: 10 to 20 mg/day; QUE: 300 to 700 mg/
day) [26], ziprasidone (HGHJ, OLZ: 10 to 20 mg/day;
ZIP: 80 to 160 mg/day) [27], Aripiprazole (HGLB, OLZ:
15 to 20 mg/day; ARI: 15 to 30 mg/day) [28] and halo-
peridol (HGDH: acute treatment phase, the initial dose
titration ranges for the first 6 weeks were OLZ [5 to 10
mg/day] and HAL [l2 to 6 mg/day; for the second 6
weeks of the acute phase and for the entire continuation
phase, the allowed doses were OLZ [5 to 20 mg/day and
haloperidol 2 to 20 mg/day]) [29-31]. Table 1 presents
these studies, their sample sizes and the study duration.
Outcome measures
Change from baseline to endpoint in productivity level
was compared between olanzapine and other antipsy-
chotic treatment groups (separately versus haloperidol,
risperidone, quetiapine, ziprasidone and aripiprazole).
Productivity was defined as functional activities/work
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housekeeping, and volunteer work in the past 3 months.
Productivity level was assessed by study investigators on
a 5-point scale: 1. No useful functioning, 2. > 0 to 25%
of the time, 3. > 25% to 50% of the time, 4. > 50% to
75% of the time, 5. > 75% to 100% of the time.
Symptom severity was measured by 5 Positive and
Negative Symptom Scale (PANSS) factor scales: positive,
negative, disorganized thoughts, hostility and depression
[32].
Statistical Analysis
Change from baseline to endpoint in productivity level
was compared between olanzapine and each of the
other antipsychotic medications within the individual
study based on an Analysis of Covariance (ANCOVA)
model with terms for baseline productivity score and
treatment. Percentage of patients with > 50% to ≤75%
("moderately high”) or > 75% ("high”) productivity level
at endpoint was also compared between treatment
groups within each study using Fisher’s exact test.
The association between productivity level and treat-
ment persistence was assessed using an ANCOVA
model which included terms for baseline productivity
s c o r ea n de a r l yt r e a t m e n td i s c ontinuation status (Y/N).
In addition, this post hoc analysis used Pearson correla-
t i o n st oa s s e s st h er e l a t i o n ship between clinical out-
comes, measured by the 5 PANSS factors–positive,
negative, disorganized thoughts, hostility and depression;
and the productivity level at the end of the study.
All statistical tests were based on a 2-tailed signifi-
cance level of 0.05.
Results
Patient Baseline Characteristics
Table 1 shows baseline clinical and demographic charac-
teristics for patients in each of the 6 studies used in the
analysis. The majority of the patients were male and
Caucasian. Mean baseline PANSS scores (range = 81.0-
101.8) reflected moderate or greater illness severity for
most of the patients.
Productivity and chronically ill patients
Change in level of productivity
Baseline-to-endpoint mean change in productivity level
scores were significantly greater for olanzapine-treated
patients compared to patients treated with risperidone
in HGBG or ziprasidone (p < .05). Olanzapine-treated
patients did not significantly differ from quetiapine-, ari-
piprazole- and haloperidol-treated patients (Figure 1).
At endpoint, olanzapine-treated patients had signifi-
cantly higher rates of moderately high and high levels of
productivity (Figure 2) than risperidone-treated patients
in HGBG (p < .05), but did not significantly differ on
these measures from the ziprasidone, quetiapine, aripi-
prazole or haloperidol treatment groups.
Table 1 Summary of Baseline Demographics and PANSS Total Scores in Patients with Schizophrenia
Study HGBG HGHJ HGJB HGLB HGGN HGDN
OLZ RISP OLZ ZIP OLZ QUET OLZ ARI OLZ RISP HAL OLZ HAL
N 172 167 277 271 171 175 281 285 159 158 97 131 132
Characteristics
Age, Mean 36.02 36.41 40.05 38.24 41.67 40.45 38.3 37.3 38.40 39.5 39.8 23.53 24.00
(SD), y (10.81) (10.6) (11.59) (12.1) (9.53) (9.6) (10.50) (10.4) (7.90) (8.25) (8.32) (4.61) (4.90)
Gender (%)
Male 114
(66.3)
106
(63.5)
180
(65.0)
172
(63.5)
114
(66.7)
113
(65.1)
194
(69.0)
190
(66.7)
115
(72.3)
111
(70.3)
69
(71.1)
104
(79.4)
111
(84.1)
Female 58
(33.7)
61
(36.5)
97
(35.0)
99 (36.5) 57
(33.3)
58
(34.9)
87
(31.0)
95
(33.3)
44
(27.7)
47
(29.7)
28
(28.9)
27
(20.6)
21
(15.9)
Race (%)
Caucasian 129
(75.0)
124
(74.3)
115
(41.5)
124
(45.8)
90
(53.2)
88
(50.3)
78
(27.8)
90
(31.6)
95
(59.7)
101
(63.9)
51
(52.6)
67
(51.1)
72
(54.5)
African 35
(20.3)
36
(21.6)
78
(28.2)
66 (24.4) 64
(37.4)
65
(37.1)
87
(31.0)
90
(31.6)
43
(27.0)
43
(27.2)
31
(32.0)
49
(37.4)
50
(37.9)
Asian 1 (0.6) 1 (0.6) 2 (0.7) 3 (1.1) 0 0 0 0 5 (3.2) 2 (1.3) 1 (1.0) 4 (3.1) 5 (3.8)
Hispanic 3 (1.7) 8 (6.1) 1 (0.4) 0 13 (7.6) 17 (9.7) 96
(34.2)
84
(29.5)
13 (8.2) 6 (3.8) 9 (9.3) 8 (6.1) 4 (3.0)
Other 4 (2.3) 4 (2.4) 63
(22.7)
61 (22.5) 3 (1.8) 5 (2.9) 20 (7.1) 19 (6.7) 3 (1.9) 6 (3.8) 5 (5.2) 3 (2.3) 1 (0.8)
PANSS Total Score
Mean (SD)
96.3
(17.0)
95.7
(16.2)
99.5
(18.4)
101.8
(21.1)
84.1
(14.8)
85.2
(4.7)
95.7
(15.9)
95.0
(15.4)
82.6
(13.1)
84.1
(14.7)
82.7
(14.1)
81.0
(14.5)
82.5
(17.5)
NOTE: HGJB was 22 weeks; HGGN was 24 weeks; HGBG, HGHJ and HGLB were 28 weeks.
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Pearson correlations between each of the 5 PANSS fac-
tor scale scores and productivity level at the end of the
study are shown in Tables 2 and 3. Correlations
between productivity level and PANSS positive, negative,
disorganized thoughts, hostility and depression were sig-
nificant for all studies (p < .05) except for HGJB, in
which productivity level was not statistically significantly
associated with symptoms of hostility (.099, p < .091) or
depression (.039, p < .502). The magnitude of the corre-
lation coefficients ranged from 0.039 (productivity level
and depression; HGJB) to -0.471 (productivity level and
disorganized thoughts; HGHJ).
Treatment persistence and productivity level
Productivity level scores for study completers versus
dropouts (measuring treatment persistence) are shown
in Figure 3. Chronically ill patients who completed the
studies had statistically significantly better productivity
levels compared to dropouts in each of the 6 studies
(p < .001).
Productivity and first episode patients
First episode patients change in level of productivity
Olanzapine-treated patients showed significantly greater
baseline-to-endpoint change in productivity level com-
pared to haloperidol treated patients (p < .05) (Figure
4). This was observed in the acute phase (12 weeks) and
over the longer-term (24 weeks). At endpoint, olanza-
pine-treated patients showed significantly higher rates of
moderately high and high levels of productivity (data
not shown) than haloperidol-treated ones (p < .05).
Level of productivity and symptom severity
Pearson correlations between each of the 5 PANSS fac-
tor scale scores and productivity level at the end of the
study (Tables 2 and 3) were statistically significant for
both the acute phase and the longer-term treatment
phases (p < .001) with correlation coefficients ranging
between -0.177 (productivity level and depression in the
acute phase) and -0.502 (productivity level and negative
symptoms in the long-term phase).
Treatment persistence and productivity level
Study completers of the acute and long-term treatment
phase had statistically significantly better productivity
level scores compared to study dropouts (p < .05) (data
not shown).
Discussion
This is the first study to evaluate improvement in pro-
ductivity among patients with schizophrenia treated
with various antipsychotics. Using data from 6 rando-
mized, double-blind clinical trials of antipsychotic ther-
apy, this post hoc investigation detected significant
differences between olanzapine and some of the studied
antipsychotics on improvement in level of productivity.
Change in level of productivity from baseline was signif-
icantly greater in both chronically ill and first episode
patients with schizophrenia treated with olanzapine
compared with some of the other antipsychotics. In
chronically ill patients, olanzapine treatment was asso-
ciated with significantly greater improvement in produc-
tivity levels compared to risperidone and ziprasidone,
but not with quetiapine or aripiprazole. Higher rates of
moderately high and high productivity levels at endpoint
were also observed with olanzapine- compared to risper-
idone treatment. For first episode patients treated with
olanzapine, significantly higher rates of moderately high
and high productivity at endpoint were observed during
the acute phase and the long-term treatment phase
compared to haloperidol-treated patients.
Current findings are consistent with those reported in
a randomized, open label, flexible dose, multi-center
study of outpatients with schizophrenia who were
assigned to a 1-year treatment with olanzapine or risper-
idone [33]. In that study, the greatest treatment group
difference was found on the occupational/employment
outcome measure (p = 0.0024). The present findings
are, however, inconsistent with two other schizophrenia
studies in which the olanzapine- and risperidone-treated
patients did not significantly differ on employment out-
comes [34] or job skills learning [35]. This inconsistency
may be related to methodological differences and espe-
cially to differences in the definition of productivity. For
example, we used an ordinal measure of productivity,
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Figure 1 By-study comparison of baseline-to-endpoint change
in productivity level in olanzapine-treated versus other-treated
chronically ill patients with schizophrenia. Comparison between
olanzapine and each of the other antipsychotics–aripiprazole,
haloperidol, risperidone, quetiapine, and ziprasidone–demonstrated
that olanzapine was consistently associated with higher mean
changes in baseline-to-endpoint productivity level. Productivity level
was assessed by study investigators on a 5-point scale, with scale
scores corresponding to how often functional activities can be
performed: 1, no useful functioning; 2, > 0% to ≤25% of the time; 3,
> 25% to ≤50% of the time; 4, > 50% to ≤75% of the time; and 5,
>75% to ≤100% of the time. Abbreviations: ARI = aripiprazole, HAL
= haloperidol, OLZ = olanzapine, RIS = risperidone, QUE =
quetiapine, ZIP = ziprasidone. *HGBG, HGHJ -p < .05.
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Figure 2 By-study comparison of endpoint productivity level in olanzapine-treated versus other-treated chronically ill patients with
schizophrenia. Comparison between olanzapine and each of the other antipsychotics–aripiprazole, haloperidol, risperidone, quetiapine, and
ziprasidone, more patients treated with olanzapine consistently had moderately high (>50% to 75% of the time) (a) and high productivity (>75%
to 100% of the time) (b) at endpoint. Abbreviations: ARI = apripiprazole, HAL = haloperidol OLZ = olanzapine, RIS = risperidone, QUE =
quetiapine, ZIP = ziprasidone. *HGBG -p < .05.
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paid activity such as volunteer work or being a student,
thus possibly being more sensitive to change than the
dichotomous measure (i.e., working for pay vs. not
working) used previously [33].
We also found significant associations between pro-
ductivity level and improvement in symptom severity
levels among chronically ill and first episode patients.
These findings are consistent with previous schizophre-
nia research in which symptom improvement and symp-
tom remission were shown to be associated with better
functional outcomes [36-39]. While our study found sig-
nificant associations between productivity level and dis-
organized thinking, positive symptoms and negative
symptoms, previous research has shown that negative
symptoms have a more robust link to functional out-
comes, with lower PANSS negative symptoms being
able to predict functional remission [36] and paid
employment [40-43]. Conversely, poorer employment
and occupational functioning were previously found to
be strongly predicted by severe negative symptoms
[40,42,43].
Our analysis also found significant associations
between productivity level and persistence on therapy,
defined as study completion. In each of the 6 trials,
which ranged between 12 (for acute phase) and 28
weeks in duration, the completers had significantly
greater improvement in productivity level than patients
who dropped out of the study. These results are consis-
tent with previous studies showing that longer duration
of antipsychotic treatment is correlated with better
functional outcomes, including better occupational func-
tioning, among patients with schizophrenia [15].
T h ec u r r e n ts t u d yf o u n da na d v a n t a g ef o ro l a n z a p i n e
therapy on improving productively level compared to
treatment with risperidone, ziprasidone, and haloperidol,
but not when compared with quetiapine and aripipra-
zole. Although our post hoc exploratory analysis cannot
clarify the underlying drivers of the current results, the
findings can be explained using the link previously
shown between longer treatment duration and better
clinical efficacy in the treatment of patients with schizo-
phrenia [21,22,44-46]. In meta-analytical studies of anti-
psychotic therapy for schizophrenia, which incorporated
data from numerous randomized clinical trials, olanza-
pine was found to confer greater efficacy compared to
haloperidol [17] risperidone and ziprasidone [18].
Furthermore, patients treated with olanzapine were con-
sistently found to stay longer on treatment compared to
those treated with haloperidol [23,31,44-49], risperidone
[21,23,24,28,48-56] and ziprasidone [21,27,57-59]. Thus,
antipsychotic treatment choice may influence patients’
improvement in symptom severity, their treatment dura-
tion and their functional outcomes as measured, in this
study, by productivity levels.
Table 2 Pearson Correlations of Productivity Level with PANSS Factor Scores at Endpoint - Chronically Ill Patients
PANSS Factors HGBG
(n = 307)
HGHJ
(n = 507)
HGJB
(n = 288)
HGLB
(n = 516)
HGGN
(n = 358)
Negative Symptoms -0.34 [p < .0001] -0.447 [p < .0001] -0.31 [p < .0001] -0.262 [p < .0001] -0.291 [p < .0001]
Positive Symptoms -0.37 [p < .0001] -0.423 [p < .0001] -0.217 [p < .0002] -0.306 [p < .0001] -0.25 [p < .0001]
Disorganized Thoughts -0.328 [p < .0001] -0.471 [p < .0001] -0.339 [p < .0001] -0.334 [p < .0001] -0.363 [p < .0001]
Hostility -0.356 [p < .0001] -0.292 [p < .0001] -0.099 [p < 0.091] -0.245 [p < .0001] -0.159 [p < .0025]
Depression -0.184 [p=.0012] -0.202 [p < .0001] 0.039 [p < 0.502] -0.185 [p < .0001] -0.114 [p < .0308]
NOTE: HGBG, HGHJ, HGJB, HGLB, and HGGN = Study Codes
Table 3 Pearson Correlations of Productivity Level with
PANSS Factor Scores at Endpoint - First Episode Patients
PANSS Factors HGDH-Acute
(n = 221)
HGDH-Long-Term
(n = 221)
Negative Symptoms -0.347 [p < .0001] -0.502 [p < .0001]
Positive Symptoms -0.414 [p < .0001] -0.493 [p < .0001]
Disorganized Thoughts -0.374 [p < .0001] -0.474 [p < .0001]
Hostility -0.22 [p < .0001] -0.318 [p < .0001]
Depression -0.177 [p < .0001] -0.296 [p < .0001]
NOTE: HGDH = Study Code
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Figure 3 By-study comparison of mean productivity score of
completers versus dropouts in chronically ill patients with
schizophrenia treated with antipsychotics. Comparison between
completers and dropouts showed that chronically ill patients who
completed the studies had better productivity levels in each of the
5 studies. Abbreviations: ARI = aripiprazole, HAL = haloperidol, OLZ
= olanzapine, RIS = risperidone, QUE = quetiapine, ZIP =
ziprasidone. ** p < .001.
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post hoc analysis of 6 randomized, double-blind clinical
trials composed of chronically ill patients with schizo-
phrenia and first episode schizophrenic patients studied
over different treatment durations [between 12 (for
acute phase) and 28 weeks]. The current findings will
require replication in studies assessing these outcomes
in an a priori manner. Second, the current analysis was
conducted in randomized clinical trials, thus it is
unclear if the findings may generalize to schizophrenia
patients treated in usual care settings. Lastly, as this
research is the first to systematically investigate the pro-
ductivity levels in treatment of schizophrenia, patients’
productivity level was assessed with a single item with 5
response options and the reliability and validity of this
productivity measure has not been established yet.
Conclusions
Current findings suggest that antipsychotic medications
may significantly differ on beneficial impact on productiv-
ity level in the treatment of patients with schizophrenia,
and highlight the link between clinical and functional out-
comes, showing significant associations between higher
productivity, lower symptom severity and better persis-
tence on therapy. This post hoc analysis suggests an
advantage for olanzapine therapy over several other anti-
psychotics on improving productivity levels among chroni-
cally ill and first episode patients with schizophrenia. This
finding will require replication in future research.
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